Back to IVBXFView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
2 competitors in Relapsed or Refractory Multiple Myeloma
View Full LandscapeDrug Information
Target Indication
Relapsed or Refractory Multiple Myeloma
Clinical Trial
NCT07623798Last updated: 10/6/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Aflibercept OphthalmicPhase 3
Neovascular Age-related Macular Degeneration
tegafur, Gimeracil and Oteracil Potassium CapsulesPhase 3
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Investigator's choice of therapyPhase 3
Colorectal Cancer
PicankibartPhase 3
Plaque Psoriasis
FebuxostatPhase 3
Gout
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts